Executive Management

John V. Oyler, Founder & CEO

John V. Oyler

Founder & CEO

  • Has served as CEO and Director since founding BeiGene in 2010
  • Founder & CEO of BioDuro, 700-person integrated research CRO in Beijing, sold to Pharmaceutical Product Development Inc. with attractive returns (2005-2009)
  • CEO of Galenea, Boston biotech started from MIT with funding from Otsuka, (2002-2004)
  • Founder, President of Telephia, sold to Nielsen (1997-2002)
  • Co-CEO of Genta (GNTA), publicly-traded oncology company that grew in late ’90s to $1.7 billion in revenues (1997-1998)
  • Began career at McKinsey & Company
  • MBA from Stanford University
  • B.S. from Massachusetts Institute of Technology
Xiaodong Wang, Ph.D., Founder & Chairman SAB

Xiaodong Wang, Ph.D.

Founder & Chairman of Scientific Advisory Board

  • Founded BeiGene in 2010, and has served as Chairman of Scientific Advisory Board since 2011
  • Founding Director & Architect of 700-person team at the National Institute of Biological Sciences (NIBS) in Beijing (2003-present)
  • Howard Hughes Medical Institute Investigator, George L. MacGregor Distinguished Chair in Biomedical Sciences (1997-2010) and Professor in Biomedical Sciences (2001-2010) at University of Texas Southwestern Medical Center
  • Member of National Academy of Sciences, USA
  • Foreign associate of Chinese Academy of Sciences
  • Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in US
  • Ph.D. in Biochemistry from University of Texas Southwestern Medical Center
  • B.S. in Biology from Beijing Normal University
Howard Liang, Ph.D., CFO and Chief Strategy Officer

Howard Liang, Ph.D.

CFO and Chief Strategy Officer

  • Former Managing Director and Head of Biotechnology Equity Research at Leerink Partners
  • Institutional Investor All-America Research Team, Biotechnology / Mid- & Small-Cap, 2015; Bloomberg Markets Top US Analysts in Biotechnology, 2012; Wall Street Journal “Best of the Street” in Biotechnology and Pharmaceuticals, 2010 and in Biotechnology, 2008
  • Senior biotechnology analyst at AG Edwards, JMP Securities; Associate Analyst at Prudential Securities covering major and specialty pharmaceuticals
  • Senior Scientist at Abbott Laboratories and member of industry’s leading structure-based drug design teams; authored review and 13 papers including six in Nature, Science, and Proceedings of National Academy of Sciences
  • M.B.A., and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago
  • B.S. in Chemistry from Peking University
Eric Hedrick (2)

Eric Hedrick, M.D.

Chief Advisor

  • Former Chief Medical Officer at Epizyme
  • VP of Oncology Development at Pharmacyclics
  • Group Medical Director at Genentech
  • Attending Physician in Hematology Service at Memorial Sloan-Kettering Cancer Center
  • M.D. from University of Maryland School of Medicine

Amy Peterson, M.D

CMO, Immuno-oncology

  • Former Vice President of Clinical Development at Medivation
  • Former Associate Group Medical Director at Genentech
  • Former Instructor of Medicine in Oncology at the University of Chicago
  • Former residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago
  • M.D. from Thomas Jefferson University in Philadelphia, PA
  • Bachelor of Arts from Wesleyan University in Middletown, CT
Jane Huang-01 (2)

Jane Huang, M.D.

CMO, Hematology

  • Former Vice President and Head of Clinical Development at Acerta Pharma (a subsidiary of Astra Zeneca)
  • Former Group Medical Director, Product Development-Oncology at Genentech (a Member of the Roche Group)
  • Adjunct Clinical Assistant Professor, Thoracic Oncology, at Stanford University
  • Board Certified in Hematology, Oncology, and Internal Medicine
  • Fellowship in Hematology and Oncology and Residency in Internal Medicine at Stanford University
  • M.D. from University of Washington School of Medicine
  • Bachelor of Science degree with Honors in Biological Sciences from Stanford University
Wendy Yan, Senior Vice President, Head of Regulatory Affairs

Wendy Yan

SVP, Global Head of Regulatory Affairs

  • More than 22 years of regulatory affairs experience at a number of multinational pharmaceutical companies
  • Former Director, Head of Regulatory Affairs China, Global Regulatory Strategist at Bayer Healthcare Global R&D Center
  • Director, Head of Regulatory Affairs at GlaxoSmithKline Pharmaceuticals China
  • Senior Regulatory Affairs Manager at AstraZeneca
  • M.B.A. at Staffordshire University
  • Bachelor of Medicine at Beijing Traditional Chinese Medicine University
  • Licensed pharmacist
Lai Wang, Ph.D. Head of Discovery Biomarkers & In Vivo Pharmacology

Lai Wang, Ph.D.

SVP, Head of China Development

  • 10 years’ experience in biotech industry and over 20 years in cancer research
  • Former Director of Research at Joyant Pharmaceuticals
  • Post-doc with Xiaodong Wang at Howard Hughes Medical Institute
  • Ph.D. from University of Texas Health Science Center at San Antonio
  • B.S. from Fudan University in 1996

June Yan

SVP, GM of Commercial in China

  • Former General Manager of Celgene China
  • Former Vice President in several areas of key importance at Lilly China, including the Bio-Medicines Business Unit, the CNS Business Unit, and Ethics & Compliance. Also, former Director of Business Transformation and Sales Operations, Hong Kong General Manager, Asia Mid-Size Countries Marketing Director, and Marketing and Sales Management at Lilly USA
  • MBA in Marketing/Finance from University of Maryland
  • S. in Biochemistry from University of Maryland
  • B.S. in Polymer Engineering from Shanghai Jiao Tong University
Ji Li

Ji Li, Ph.D.

EVP, Global Head of Business Development

  • More than 18 years of Business Development and R&D experience in biopharma industry
  • Former member of the Board of Directors of BeiGene, as a representative for Merck, up until BeiGene’s IPO in February 2016
  • Former Vice President of Business Development and Licensing at Merck & Co. Inc
  • Former Executive Licensing Director, External R&D at Amgen
  • Key member of Amgen research team discovered and validated the RANKL signaling pathway that has led to the development of Denosumab, the current standard of care therapy for osteoporosis, cancer bone metastasis and other bone loss indications.
  • Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York
  • B.S. in Pharmacology from Shanghai Medical University

Scott A. Samuels, Esq.

SVP, General Counsel

  • Former Assistant General Counsel and Acting General Counsel at ARIAD Pharmaceuticals
  • 17 years’ experience representing life science companies at Mintz Levin, including 9 years as a partner in the firm’s corporate and securities practice
  • J.D. with distinction from George Mason University
  • Bachelor of Arts in Philosophy from Cornell University